Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

NRIX Nurix Therapeutics Inc

Price (delayed)

$12.16

Market cap

$927.02M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.8

Enterprise value

$876.83M

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer ...

Highlights
NRIX's debt is down by 9% year-on-year and by 6% since the previous quarter
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
NRIX's quick ratio has surged by 119% year-on-year but it is down by 3.9% since the previous quarter
The net income has declined by 44% year-on-year and by 8% since the previous quarter

Key stats

What are the main financial stats of NRIX
Market
Shares outstanding
76.24M
Market cap
$927.02M
Enterprise value
$876.83M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.92
Price to sales (P/S)
18.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.54
Earnings
Revenue
$56.42M
Gross profit
$56.42M
Operating income
-$230.67M
Net income
-$208.4M
EBIT
-$208.22M
EBITDA
-$191.55M
Free cash flow
-$201.59M
Per share
EPS
-$2.8
EPS diluted
-$2.8
Free cash flow per share
-$2.41
Book value per share
$6.34
Revenue per share
$0.68
TBVPS
$7.36
Balance sheet
Total assets
$615.04M
Total liabilities
$134.13M
Debt
$26.62M
Equity
$480.92M
Working capital
$473.72M
Liquidity
Debt to equity
0.06
Current ratio
6.26
Quick ratio
6.12
Net debt/EBITDA
0.26
Margins
EBITDA margin
-339.5%
Gross margin
100%
Net margin
-369.4%
Operating margin
-408.9%
Efficiency
Return on assets
-36.1%
Return on equity
-47.5%
Return on invested capital
-50.1%
Return on capital employed
-39.7%
Return on sales
-369.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

NRIX stock price

How has the Nurix Therapeutics stock price performed over time
Intraday
0.66%
1 week
21.12%
1 month
7.9%
1 year
-23.76%
YTD
-35.46%
QTD
2.36%

Financial performance

How have Nurix Therapeutics's revenue and profit performed over time
Revenue
$56.42M
Gross profit
$56.42M
Operating income
-$230.67M
Net income
-$208.4M
Gross margin
100%
Net margin
-369.4%
Nurix Therapeutics's operating margin has shrunk by 110% YoY and by 4.7% QoQ
NRIX's net margin has dropped by 106% year-on-year and by 4.1% since the previous quarter
The operating income has declined by 47% year-on-year and by 8% since the previous quarter
The net income has declined by 44% year-on-year and by 8% since the previous quarter

Price vs fundamentals

How does NRIX's price correlate with its fundamentals

Growth

What is Nurix Therapeutics's growth rate over time

Valuation

What is Nurix Therapeutics stock price valuation
P/E
N/A
P/B
1.92
P/S
18.01
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.54
NRIX's EPS is down by 5% year-on-year but it is up by 2.8% since the previous quarter
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 3.0 and 34% less than its 5-year quarterly average of 2.9
The revenue has contracted by 30% YoY but it has grown by 3.4% from the previous quarter
The stock's price to sales (P/S) is 30% less than its 5-year quarterly average of 25.7 and 27% less than its last 4 quarters average of 24.6

Efficiency

How efficient is Nurix Therapeutics business performance
NRIX's return on sales has dropped by 106% year-on-year and by 4.1% since the previous quarter
The ROE has grown by 29% YoY and by 11% from the previous quarter
NRIX's return on invested capital is up by 23% year-on-year and by 10% since the previous quarter
NRIX's return on assets is up by 17% year-on-year and by 6% since the previous quarter

Dividends

What is NRIX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for NRIX.

Financial health

How did Nurix Therapeutics financials performed over time
NRIX's current ratio has surged by 119% year-on-year but it is down by 3.1% since the previous quarter
NRIX's quick ratio has surged by 119% year-on-year but it is down by 3.9% since the previous quarter
NRIX's debt is 94% smaller than its equity
NRIX's equity has surged by 185% year-on-year but it is down by 9% since the previous quarter
The debt to equity has dropped by 65% year-on-year but it has increased by 20% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.